172 related articles for article (PubMed ID: 21492231)
1. Interaction between linezolid and Mycobacterium tuberculosis in an experimental in vitro model.
Cremades R; Rodríguez JC; Garcia-Pachón E; Galiana A; Ruiz-García M; López P; Royo G
APMIS; 2011 Apr; 119(4-5):304-8. PubMed ID: 21492231
[TBL] [Abstract][Full Text] [Related]
2. [Effect of linezolid in combination with isoniazid and rifampicin against multidrug resistant Mycobacterium tuberculosis clinical isolates].
Coban AY; Bilgin K; Uzun M; Durupinar B
Mikrobiyol Bul; 2009 Apr; 43(2):293-7. PubMed ID: 19621615
[TBL] [Abstract][Full Text] [Related]
3. Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis.
Nam HS; Koh WJ; Kwon OJ; Cho SN; Shim TS
Int J Antimicrob Agents; 2009 Jan; 33(1):92-3. PubMed ID: 18789655
[No Abstract] [Full Text] [Related]
4. In vitro activity of linezolid against multidrug-resistant Mycobacterium tuberculosis isolates.
Erturan Z; Uzun M
Int J Antimicrob Agents; 2005 Jul; 26(1):78-80. PubMed ID: 15950439
[TBL] [Abstract][Full Text] [Related]
5. In vitro efficacy of Linezolid on clinical strains of Mycobacterium tuberculosis and other mycobacteria.
Molicotti P; Ortu S; Bua A; Cannas S; Sechi LA; Zanetti S
New Microbiol; 2006 Oct; 29(4):275-80. PubMed ID: 17201094
[TBL] [Abstract][Full Text] [Related]
6. First linezolid-resistant clinical isolates of Mycobacterium tuberculosis.
Richter E; Rüsch-Gerdes S; Hillemann D
Antimicrob Agents Chemother; 2007 Apr; 51(4):1534-6. PubMed ID: 17242139
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of the mycobacterium efficacy of linezolid in vitro].
Huang HR; Yu X; Jiang GL; Dai GM; Bi ZQ; Ma Y
Zhonghua Jie He He Hu Xi Za Zhi; 2011 Aug; 34(8):575-8. PubMed ID: 22168977
[TBL] [Abstract][Full Text] [Related]
8. [The analysis of clinical data about the treatment of linezolid against tuberculosis].
Nie WJ; Chu NH
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Aug; 36(8):601-3. PubMed ID: 24252739
[No Abstract] [Full Text] [Related]
9. In vitro activity of linezolid against Mycobacterium tuberculosis strains isoalted from Western Turkey.
Ermertcan S; Hosgor-Limoncu M; Erac B; Tasli H; Cavusoglu C; Bozkurt H
Jpn J Infect Dis; 2009 Sep; 62(5):384-5. PubMed ID: 19762990
[TBL] [Abstract][Full Text] [Related]
10. Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis.
Rodríguez JC; Cebrián L; López M; Ruiz M; Jiménez I; Royo G
J Antimicrob Chemother; 2004 Mar; 53(3):441-4. PubMed ID: 14963069
[TBL] [Abstract][Full Text] [Related]
11. Post-antibiotic effects of linezolid and other agents against Mycobacterium tuberculosis.
Hui M; Au-Yeang C; Wong KT; Chan CY; Yew WW; Leung CC
Int J Antimicrob Agents; 2008 Apr; 31(4):395-6. PubMed ID: 18272351
[No Abstract] [Full Text] [Related]
12. In vitro activity of linezolid against multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant (XDR)-TB isolates.
Prammananan T; Chaiprasert A; Leechawengwongs M
Int J Antimicrob Agents; 2009 Feb; 33(2):190-1. PubMed ID: 18945598
[No Abstract] [Full Text] [Related]
13. In vitro activity of linezolid against clinical isolates of Mycobacterium tuberculosis, including multidrug-resistant and extensively drug-resistant strains from Beijing, China.
Yang C; Lei H; Wang D; Meng X; He J; Tong A; Zhu L; Jiang Y; Dong M
Jpn J Infect Dis; 2012; 65(3):240-2. PubMed ID: 22627306
[TBL] [Abstract][Full Text] [Related]
14. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years.
Huang TS; Liu YC; Sy CL; Chen YS; Tu HZ; Chen BC
Antimicrob Agents Chemother; 2008 Jun; 52(6):2226-7. PubMed ID: 18391030
[TBL] [Abstract][Full Text] [Related]
15. In vitro activities of PNU-100480 and linezolid against drug-susceptible and drug-resistant Mycobacterium tuberculosis isolates.
Yip PC; Kam KM; Lam ET; Chan RC; Yew WW
Int J Antimicrob Agents; 2013 Jul; 42(1):96-7. PubMed ID: 23684005
[No Abstract] [Full Text] [Related]
16. In vitro susceptibility of Mycobacterium tuberculosis clinical isolates to garenoxacin and DA-7867.
Vera-Cabrera L; Castro-Garza J; Rendon A; Ocampo-Candiani J; Welsh O; Choi SH; Blackwood K; Molina-Torres C
Antimicrob Agents Chemother; 2005 Oct; 49(10):4351-3. PubMed ID: 16189119
[TBL] [Abstract][Full Text] [Related]
17. rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains.
Beckert P; Hillemann D; Kohl TA; Kalinowski J; Richter E; Niemann S; Feuerriegel S
Antimicrob Agents Chemother; 2012 May; 56(5):2743-5. PubMed ID: 22371899
[TBL] [Abstract][Full Text] [Related]
18. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs.
Alcalá L; Ruiz-Serrano MJ; Pérez-Fernández Turégano C; García De Viedma D; Díaz-Infantes M; Marín-Arriaza M; Bouza E
Antimicrob Agents Chemother; 2003 Jan; 47(1):416-7. PubMed ID: 12499228
[TBL] [Abstract][Full Text] [Related]
19. Activity of RBx 7644 and RBx 8700, new investigational oxazolidinones, against Mycobacterium tuberculosis infected murine macrophages.
Sood R; Rao M; Singhal S; Rattan A
Int J Antimicrob Agents; 2005 Jun; 25(6):464-8. PubMed ID: 15885988
[TBL] [Abstract][Full Text] [Related]
20. In vitro synergy between linezolid and clarithromycin against Mycobacterium tuberculosis.
Bolhuis MS; van der Laan T; Kosterink JG; van der Werf TS; van Soolingen D; Alffenaar JW
Eur Respir J; 2014 Sep; 44(3):808-11. PubMed ID: 24791826
[No Abstract] [Full Text] [Related]
[Next] [New Search]
